Radiology
September 1, 2026 · via Europe PMC
How I Do It: Identifying Signs to Differentiate Uterine Sarcoma (Leiomyosarcoma) from Leiomyomas at MRI.
Hindman N, Tong A, Huang K.
AI summary — for doctors, generated from the abstract only
Contrast-enhanced MRI with DWI and ADC detects uterine leiomyosarcoma with 88-94.6% accuracy, helping identify sarcomas before treatment of presumed fibroids.
What was studied
'How I Do It' educational review describing MRI signs and application of the Radiology 2023 consensus algorithm to differentiate leiomyosarcoma from leiomyomas.
Key findings
- Uterine sarcoma risk may be as high as 1 in 770 women having surgery for presumed fibroids
- Contrast-enhanced MRI with DWI/ADC has 88%-94.6% accuracy for leiomyosarcoma detection
- The 2023 consensus algorithm has been preliminarily validated; authors add practical nuances
Clinical relevance
This supports MRI-based risk assessment before minimally invasive or morcellation-based fibroid treatment, in partnership with radiology.
Who should care
Limitations
Educational review; the algorithm's validation is described as preliminary.
A careful pre-treatment MRI can help avoid unknowingly morcellating a uterine sarcoma.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
The prevalence of uterine sarcoma, typically leiomyosarcoma, is greater than previously believed, with current data indicating a risk as high as one in 770 women undergoing surgery for presumed leiomyomas (uterine fibroids). Presurgical detection of uterine sarcoma is an important clinical concern for gynecologists and gynecologic oncologists worldwide. Inadvertent minimally invasive treatment of unsuspected uterine leiomyosarcoma may delay definitive therapy or lead to disease dissemination. Contrast-enhanced MRI with diffusion-weighted imaging and apparent diffusion coefficient measurement provides high accuracy (88%-94.6%) in detecting uterine leiomyosarcoma, making radiologists valuable partners to gynecologists in risk assessment and disease management. The algorithm outlined in the Radiology 2023 MRI Evaluation of Uterine Masses for Risk of Leiomyosarcoma consensus statement has been preliminarily validated, and the authors present additional nuances to enhance its application in clinical practice.
The prevalence of uterine sarcoma, typically leiomyosarcoma, is greater than previously believed, with current data indicating a risk as high as one in 770 women undergoing surgery for presumed leiomyomas (uterine fibroids). Presurgical detection of uterine sarcoma is an important clinical concern for gynecologists and gynecologic oncologists worldwide. Inadvertent minimally invasive treatment of unsuspected uterine leiomyosarcoma may delay definitive therapy or lead to disease dissemination. Contrast-enhanced MRI with diffusion-weighted imaging and apparent diffusion coefficient measurement provides high accuracy (88%-94.6%) in detecting uterine leiomyosarcoma, making radiologists valuable partners to gynecologists in risk assessment and disease management. The algorithm outlined in the Radiology 2023 MRI Evaluation of Uterine Masses for Risk of Leiomyosarcoma consensus statement has been preliminarily validated, and the authors present additional nuances to enhance its application in clinical practice.
DOI
10.1148/radiol.252877
PMID
42770820
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed